Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy
Authors
Keywords
-
Journal
ANNALS OF NUCLEAR MEDICINE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-28
DOI
10.1007/s12149-023-01874-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial
- (2022) Phillip Hsin Kuo et al. JOURNAL OF NUCLEAR MEDICINE
- Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T
- (2022) Philipp E. Hartrampf et al. Cancers
- Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
- (2022) Philipp E. Hartrampf et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.
- (2022) Phillip Kuo et al. JOURNAL OF CLINICAL ONCOLOGY
- PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
- (2022) James P Buteau et al. LANCET ONCOLOGY
- Is18F-FDG PET needed to assess177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis
- (2022) Robert Seifert et al. JOURNAL OF NUCLEAR MEDICINE
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- The VISION Forward: Recognition and Implication of PSMA-/FDG+ mCRPC
- (2021) Hossein Jadvar JOURNAL OF NUCLEAR MEDICINE
- Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
- (2021) Sebastian Hoberück et al. EJNMMI Research
- Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
- (2020) Kerstin Michalski et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
- (2019) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
- (2017) Matthias Eiber et al. JOURNAL OF NUCLEAR MEDICINE
- F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
- (2016) Frederik L. Giesel et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Is There Use for FDG-PET in Prostate Cancer?
- (2016) Hossein Jadvar SEMINARS IN NUCLEAR MEDICINE
- Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations
- (2013) Hossein Jadvar EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now